Jupiter Neurosciences (JUNS) Return on Capital Employed (2024 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Return on Capital Employed of 267.87% for Q4 2025, up 53925.0% year-over-year from N/an in Q4 2024, and up 126.7% quarter-over-quarter from 1003.31% in Q3 2025.
Jupiter Neurosciences (JUNS) Return on Capital Employed (2024 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Return on Capital Employed for 2 consecutive years, with 267.87% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed rose 53925.0% year-over-year to 267.87%; the TTM figure through Dec 2025 stood at 267.87% (up 53925.0% YoY), while the FY2025 annual figure was 588.94%, up 85398.0% from the prior year.
- Return on Capital Employed improved to 267.87% in Q4 2025 per JUNS's latest filing, from 1003.31% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 267.87% in Q4 2025 and bottomed at 1003.31% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | -1,327.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 267.87% |
| Sep 30, 2025 | -1,003.31% |
| Jun 30, 2025 | -313.19% |
| Mar 31, 2025 | -109.59% |
| Dec 31, 2024 | -271.38% |